Patents by Inventor Patrick W. Gray
Patrick W. Gray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6498015Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C-C chemokine designated Macrophage Derived Chemokine (MDC), and polypeptide analogs thereof. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein, and polypeptide analogs thereof. Also provided are antibodies reactive with the chemokine and methods of making and using all of the foregoing.Type: GrantFiled: September 26, 1997Date of Patent: December 24, 2002Assignee: ICOS CorporationInventors: Ronald Godiska, Patrick W. Gray, Carol J. Raport
-
Publication number: 20020177231Abstract: Disclosed are novel leupaxin polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, host cell transformed with the polynucleotides, methods to produce the polypeptides, antibodies and binding partners specific for the polypeptides, methods to identify modulators of the polypeptides, and methods to identify modulators of polypeptide expression.Type: ApplicationFiled: December 15, 1998Publication date: November 28, 2002Inventors: DONALD E. STAUNTON, BRIAN P. LIPSKY, PATRICK W. GRAY
-
Publication number: 20020150888Abstract: The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, viral infection, AIDS, and other inflammatory conditions.Type: ApplicationFiled: March 26, 2002Publication date: October 17, 2002Inventors: Patrick W. Gray, Vicki L. Schweickart, Carol J. Raport
-
Publication number: 20020102642Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C—C chemokine designated MCP-5. Also provided are purified and isolated chemokine protein, fragments and polypeptide analogs thereof, antibodies thereto, and materials and methods for the recombinant production thereof. These products are useful in therapeutic, diagnostic and medical imaging applications.Type: ApplicationFiled: June 1, 2001Publication date: August 1, 2002Applicant: ICOS CorporationInventors: Ronald Godiska, Patrick W. Gray
-
Patent number: 6399571Abstract: The present invention provides chitin-binding fragments of human chitinase, fragment analogs, purified and isolated polynucleotide sequences encoding such fragments and analogs, and materials and methods for the recombinant production of human chitinase fragment products which are expected to be useful as in products for detecting chitin, binding chitin, and treating fungal infections or for development of products useful for treating the same.Type: GrantFiled: March 12, 1999Date of Patent: June 4, 2002Assignee: ICOS CorporationInventors: Patrick W. Gray, Larry W. Tjoelker
-
Patent number: 6372212Abstract: The present invention provides purified and isolated polynucleotide sequences encoding human chitinase. Also provided are materials and methods for the recombinant production of human chitinase products which are expected to be useful as products for treating fungal infections or for development of products useful for treating the same.Type: GrantFiled: June 16, 1997Date of Patent: April 16, 2002Assignee: ICOS CorporationInventor: Patrick W. Gray
-
Patent number: 6348574Abstract: DNA sequences encoding seven novel seven transmembrane receptors and variants thereof are disclosed as well as materials and methods for production of the same by recombinant techniques. Antibody substances specific for each of the seven transmembrane receptors are disclosed as useful for the modulation of the ligand/receptor binding reactions of the receptors.Type: GrantFiled: June 1, 1998Date of Patent: February 19, 2002Assignee: ICOS CorporationInventors: Ronald Godiska, Patrick W. Gray, Vicki Louise Schweickart
-
Patent number: 6320023Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C-C chemokine designated MDC. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein.Type: GrantFiled: June 7, 1995Date of Patent: November 20, 2001Assignee: ICOS CorporationInventors: Ronald Godiska, Patrick W. Gray
-
Patent number: 6268477Abstract: The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, viral infection, AIDS, and other inflammatory conditions.Type: GrantFiled: June 7, 1996Date of Patent: July 31, 2001Assignee: Icos CorporationInventors: Patrick W. Gray, Vicki L. Schweickart, Carol J. Raport
-
Patent number: 6265184Abstract: The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, and other inflammatory conditions.Type: GrantFiled: December 20, 1995Date of Patent: July 24, 2001Assignee: Icos CorporationInventors: Patrick W. Gray, Vicki L. Schweickart, Carol J. Raport
-
Patent number: 6200951Abstract: The present invention provides chitin-binding fragments of human chitinase, fragment analogs, purified and isolated polynucleotide sequences encoding such fragments and analogs, and materials and methods for the recombinant production of human chitinase fragment products which are expected to be useful as in products for detecting chitin, binding chitin, and treating fungal infections or for development of products useful for treating the same.Type: GrantFiled: March 12, 1998Date of Patent: March 13, 2001Assignee: ICOS CorporationInventors: Patrick W. Gray, Larry W. Tjoelker
-
Patent number: 6177543Abstract: Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein enable the economical preparation of compositions containing uniform lymphotoxin polypeptides and variant lymphotoxins having amino acid sequences that differ from those found in nature. The lymphotoxins are purified to a specific activity of 2-10×107 units/mg of protein by purification using a novel immobilized, lymphotoxin-neutralizing monoclonal antibody.Type: GrantFiled: March 19, 1998Date of Patent: January 23, 2001Assignee: Genentech, Inc.Inventors: Bharat B. Aggarwal, Patrick W. Gray, Glenn E. Nedwin
-
Patent number: 6107475Abstract: DNA sequences encoding seven novel seven transmembrane receptors and variants thereof are disclosed as well as materials and methods for production of the same by recombinant techniques. Antibody substances specific for each of the seven transmembrane receptors are disclosed as useful for the modulation of the ligand/receptor binding reactions of the receptors.Type: GrantFiled: April 26, 1999Date of Patent: August 22, 2000Assignee: ICOS CorporationInventors: Ronald Godiska, Patrick W. Gray, Vicki Louise Schweickart
-
Patent number: 5932703Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C--C chemokine designated MDC, and polypeptide analogs thereof. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein, and polypeptide analogs thereof.Type: GrantFiled: June 7, 1996Date of Patent: August 3, 1999Assignee: ICOS CorporationInventors: Ronald Godiska, Patrick W. Gray
-
Patent number: 5824509Abstract: Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein enable the economical preparation of compositions containing uniform lymphotoxin polypeptides and variant lymphotoxins having amino acid sequences that differ from those found in nature. The lymphotoxins are purified to a specific activity of 2-10.times.10.sup.7 units/mg of protein by purification using a novel immobilized, lymphotoxin-neutralizing monoclonal antibody.Type: GrantFiled: May 19, 1995Date of Patent: October 20, 1998Assignee: Genentech, Inc.Inventors: Bharat B. Aggarwal, Patrick W. Gray, Glenn E. Nedwin
-
Patent number: 5759804Abstract: DNA sequences encoding seven novel seven transmembrane receptors and variants thereof are disclosed as well as materials and methods for production of the same by recombinant techniques. Antibody substances specific for each of the seven transmembrane receptors are disclosed as useful for the modulation of the ligand/receptor binding reactions of the receptors.Type: GrantFiled: November 17, 1993Date of Patent: June 2, 1998Assignee: ICOS CorporationInventors: Ronald Godiska, Patrick W. Gray, Vicki Louise Schweickart
-
Patent number: 5690925Abstract: The present invention relates to novel, stable recombinant gamma interferons exhibiting in greater or less degree the antiviral and antiproliferative activity in humans and pH 2 labile properties characteristic of native human gamma interferon. The amino acid sequence of such an interferon comprises, from the N-terminus: ##STR1## wherein X is a methionine residue or hydrogen and Y is a glutamine residue or, where X is hydrogen, Y is either a glutamine or a pyroglutamate residue.Type: GrantFiled: March 22, 1994Date of Patent: November 25, 1997Assignee: Genentech, Inc.Inventors: Patrick W. Gray, Ernst H. Rinderknecht
-
Patent number: 5688927Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C--C chemokine designated MDC. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein.Type: GrantFiled: June 7, 1995Date of Patent: November 18, 1997Assignee: ICOS CorporationInventors: Ronald Godiska, Patrick W. Gray
-
Patent number: 5683688Abstract: Biologically active lymphotoxin polypeptides are synthesized in recombinant cell culture. Novel nucleic acid and vectors incorporating same are provided. The compositions and processes herein enable the economical preparation of compositions containing uniform lymphotoxin polypeptides and variant lymphotoxins having amino acid sequences that differ from those found in nature. The lymphotoxins are purified to a specific activity of 2-10.times.10.sup.7 units/mg of protein by purification using a novel immobilized, lymphotoxin-neutralizing monoclonal antibody.Type: GrantFiled: February 14, 1992Date of Patent: November 4, 1997Assignee: Genentech, Inc.Inventors: Bharat B. Aggarwal, Patrick W. Gray, Glenn E. Nedwin
-
Patent number: 5633145Abstract: A polypeptide is provided which is capable of binding human TNF.alpha. and which has the first three cysteine-rich subdomains, but not the fourth cysteine-rich subdomain, of the extracellular binding domain of a receptor selected from the group consisting of the 55 kD and 75 kD receptors for human TNF.alpha.. The ability of the polypeptide to bind TNF.alpha. means that it can be used for treating diseases mediated by TNF.alpha. activity, such as rheumatoid arthritis.Type: GrantFiled: May 10, 1993Date of Patent: May 27, 1997Assignee: The Mathilda and Terence Kennedy Institute of RheumatologyInventors: Marc Feldmann, Patrick W. Gray, Martin J. C. Turner, Fionula M. Brennan